erythropoietin (controlled-release, ProLease) (Alkermes/RWPRI)

N/A

Report date: 2023/02/17 20:41:20

Base Information

Drug Nameerythropoietin (controlled-release, ProLease) (Alkermes/RWPRI)
Drug Alias NameProLeaseerythropoietin(Alkermes/RWPRI)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlkermes PlcJohnson & Johnson
Active IndicationsN/A
Inactive IndicationsAnemia

Other Information

ATC CodeN/A
Related LinksN/A